Patents by Inventor Srinivas Gullapalli

Srinivas Gullapalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190031665
    Abstract: Present invention relates to novel heterocyclic compounds as indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) modulators. Compounds of the present invention inhibit tryptophan degradation by modulating IDO and/or TDO. The invention further relates to the process of their preparation, pharmaceutical composition and their use in modulating the activity of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO). The compounds of the invention can be used alone or in combination for the treatment of conditions that benefits from the inhibition of tryptophan degradation.
    Type: Application
    Filed: January 31, 2017
    Publication date: January 31, 2019
    Applicant: Emcure Pharmaceuticals Limited
    Inventors: Mukund Keshav GURJAR, Abhijit ROYCHOWDHURY, Tushar Pandurang KHALADKAR, Sangmeshwar Prabhakar SAWARGAVE, Ravindra Ashok JANRAO, Vijay Keshav KALHAPURE, Ganesh Devidas URUNKAR, Srinivas GULLAPALLI, Jayanarayan KULATHINGAL, Rammohan Reddy LEKKALA
  • Patent number: 9532988
    Abstract: The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: January 3, 2017
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Srinivas Gullapalli, Praveen Kumar Gupta, Maulik Nitinkumar Gandhi
  • Publication number: 20150105406
    Abstract: The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.
    Type: Application
    Filed: October 14, 2014
    Publication date: April 16, 2015
    Inventors: Srinivas GULLAPALLI, Praveen Kumar GUPTA, Maulik Nitinkumar GANDHI, Sravan MANDADI
  • Patent number: 8420689
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 16, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • Publication number: 20120142748
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.
    Type: Application
    Filed: January 14, 2011
    Publication date: June 7, 2012
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan MUTHUPPALANIAPPAN, Gopalan BALASUBRAMANIAN, Srinivas GULLAPALLI, Neelima Khairatkar JOSHI, Shridhar Narayanan
  • Patent number: 7951814
    Abstract: The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 31, 2011
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Meyyappan Muthuppalniappan, Abraham Thomas, Sukeerthi Kumar, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Srinivas Gullapalli
  • Patent number: 7923465
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: April 12, 2011
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • Publication number: 20090325987
    Abstract: The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: June 16, 2009
    Publication date: December 31, 2009
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Meyyappan Muthuppalniappan, Abraham Thomas, Sukeerthi Kumar, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Srinivas Gullapalli
  • Publication number: 20080234259
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
    Type: Application
    Filed: June 1, 2006
    Publication date: September 25, 2008
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • Publication number: 20080200501
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
    Type: Application
    Filed: November 2, 2007
    Publication date: August 21, 2008
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Kumar Sukeerthi, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan, Pallavi V. Kamik